Literature DB >> 9237101

Binding of copolymer 1 and myelin basic protein leads to clustering of class II MHC molecules on antigen-presenting cells.

M Fridkis-Hareli1, D Teitelbaum, I Pecht, R Arnon, M Sela.   

Abstract

Copolymer 1 (Cop 1), a synthetic copolymer of amino acids, effective in suppression of experimental allergic encephalomyelitis (EAE) and myelin basic protein (MBP), was shown to bind extensively and promiscuously to the class II MHC molecules on antigen-presenting cells (APC) without prior processing. In the case of human APC, binding has earlier been demonstrated to DR but not DQ or class I molecules. In the present study, we examined whether binding of Cop 1 and MBP affects MHC class II expression on the cell membrane. Biotinylated derivatives of these antigens were used to monitor their direct binding to MHC molecules on living APC by flow cytometry using phycoerythrin-streptavidin, while the levels of MHC surface expression were monitored by staining with FITC-conjugated anti-class I- and class II-specific antibodies. When Cop 1 or MBP were incubated with the APC, intensity of cell staining with anti-DR, but not with anti-DQ or anti-class I antibodies, was significantly increased, compared to the staining of control APC not reacted with these antigens. In contrast, staining intensity was unaffected when p84-102, a human immunodominant epitope of MBP, or ovalbumin (OVA), a protein which undergoes proteolytic degradation prior to binding, were incubated with the APC. Cycloheximide, a protein synthesis inhibitor, had no effect on the enhanced staining intensity with anti-DR antibody of cells treated with Cop 1 or MBP, whereas it inhibited the enhanced staining of both DR and DQ molecules caused by the respective antibodies, in the absence of these antigens. Brefeldin A, a protein transport inhibitor, lowered the levels of staining intensity with anti-DR and anti-DQ antibodies in both cases, with and without antigen added to the APC. Fluorescence microscopic analysis revealed that cells incubated with Cop 1 or MBP, but not with p84-102 or OVA, exhibit both bright staining of the cell membrane and clusters produced by the aggregation of DR molecules with these antigens. Taken together, these observations indicate that Cop 1 and MBP, due to their polyvalent character, lead to increased fluorescence intensity of their complexes with HLA-DR, possibly due to recruitment and clustering of previously synthesized DR molecules. This can explain the efficient binding of these antigens to the MHC class II molecules.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9237101     DOI: 10.1093/intimm/9.7.925

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  12 in total

1.  The effect of glatiramer acetate therapy on functional properties of B cells from patients with relapsing-remitting multiple sclerosis.

Authors:  Sara J Ireland; Alyssa A Guzman; Dina E O'Brien; Samuel Hughes; Benjamin Greenberg; Angela Flores; Donna Graves; Gina Remington; Elliot M Frohman; Laurie S Davis; Nancy L Monson
Journal:  JAMA Neurol       Date:  2014-11       Impact factor: 18.302

Review 2.  Mechanism and adverse effects of multiple sclerosis drugs: a review article. Part 2.

Authors:  Aryan Rafiee Zadeh; Keyvan Ghadimi; Akram Ataei; Mozhde Askari; Neda Sheikhinia; Nooshin Tavoosi; Masih Falahatian
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2019-08-15

Review 3.  The Evolving Mechanisms of Action of Glatiramer Acetate.

Authors:  Thomas Prod'homme; Scott S Zamvil
Journal:  Cold Spring Harb Perspect Med       Date:  2019-02-01       Impact factor: 6.915

Review 4.  Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis.

Authors:  Dene Simpson; Stuart Noble; Caroline Perry
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

5.  Amelioration of proteolipid protein 139-151-induced encephalomyelitis in SJL mice by modified amino acid copolymers and their mechanisms.

Authors:  Joel N H Stern; Zsolt Illés; Jayagopala Reddy; Derin B Keskin; Eric Sheu; Masha Fridkis-Hareli; Hiroyuki Nishimura; Celia F Brosnan; Laura Santambrogio; Vijay K Kuchroo; Jack L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-03       Impact factor: 11.205

6.  Glatiramer acetate protects against inflammatory synaptopathy in experimental autoimmune encephalomyelitis.

Authors:  Antonietta Gentile; Silvia Rossi; Valeria Studer; Caterina Motta; Valentina De Chiara; Alessandra Musella; Helena Sepman; Diego Fresegna; Gabriele Musumeci; Giorgio Grasselli; Nabila Haji; Sagit Weiss; Liat Hayardeny; Georgia Mandolesi; Diego Centonze
Journal:  J Neuroimmune Pharmacol       Date:  2013-01-31       Impact factor: 4.147

7.  Novel synthetic amino acid copolymers that inhibit autoantigen-specific T cell responses and suppress experimental autoimmune encephalomyelitis.

Authors:  Masha Fridkis-Hareli; Laura Santambrogio; Joel N H Stern; Lars Fugger; Celia Brosnan; Jack L Strominger
Journal:  J Clin Invest       Date:  2002-06       Impact factor: 14.808

8.  Exploring the role of microglia in mood disorders associated with experimental multiple sclerosis.

Authors:  Antonietta Gentile; Francesca De Vito; Diego Fresegna; Alessandra Musella; Fabio Buttari; Silvia Bullitta; Georgia Mandolesi; Diego Centonze
Journal:  Front Cell Neurosci       Date:  2015-06-25       Impact factor: 5.505

Review 9.  Design of peptide immunotherapies for MHC Class-II-associated autoimmune disorders.

Authors:  Masha Fridkis-Hareli
Journal:  Clin Dev Immunol       Date:  2013-11-13

Review 10.  Current and future therapies for multiple sclerosis.

Authors:  Alireza Minagar
Journal:  Scientifica (Cairo)       Date:  2013-02-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.